Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

AAB-001 in Patients With Mild to Moderate Alzheimer's Disease

This study has been completed.
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
ClinicalTrials.gov Identifier:
NCT00112073
First received: May 27, 2005
Last updated: March 12, 2012
Last verified: March 2012